Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cochlear implants cases in Indiana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 23% on average (17 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 108 | 35% |
| 2020 | 2 | 69 | 39% |
| 2021 | 4 | 112 | 44% |
Cochlear implantation, children and adults. Professional codes (what the surgeon bills): CPT 69930.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Indiana; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 33 | 2,791−11%/yr | −11%/yr | 4.01.1× | 88% | 2,910 in 2030+0.7%/yr |
| Ear tubes & middle ear surgery |
Cochlear implants in every state, and its device makers · Every procedure market in Indiana · Every state · Compare with Ohio
| 2024 |
| 115 |
| 53% |
| 2025 est. | ≈ 100 | – |
| 2026 est. | ≈ 100 | – |
| 2022 | 3 | 119 | 47% |
| 2023 | 4 | 78 | 51% |
| 2024 | 3 | 115 | 53% |
| 2025 from claims | – | 97 78–114 | 54% |
| 2026 forecast | – | 98 77–123 | 55% |
| 2027 forecast | – | 99 74–131 | 55% |
| 2028 forecast | – | 100 71–138 | 56% |
| 2029 forecast | – | 101 69–145 | 57% |
| 2030 forecast | – | 102 67–152 | 57% |
In 2025, 62% hospital outpatient, 38% surgery center.
| +4.9%/yr |
| 0.1 |
| 0% |
| 140 in 2030−3.2%/yr |
| Kansas | 5 | 140+40%/yr | +40%/yr | 0.3 | 0% | 220 in 2030+7.8%/yr |
| Minnesota | 4 | 131+1.6%/yr | +1.6%/yr | 0.3 | 0% | 180 in 2030+5.5%/yr |
| Michigan | 3 | 130−0.5%/yr | −0.5%/yr | 0.2 | 0% | 210 in 2030+8.1%/yr |
| Missouri | 4 | 129−5.7%/yr | −5.7%/yr | 0.2 | 0% | 130 in 2030−0.1%/yr |
| 10 |
| 483−5.4%/yr |
| −5.4%/yr |
| 0.72.3× |
| 52% |
| 490 in 2030+0.1%/yr |
| Sleep apnea & airway implants | 3 | 142+50%/yr | +50%/yr | 0.20.9× | 9% | 190 in 2030+4.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Smith+Nephew leads with 69% of company spending on these surgeons in 2025, −4 pts on 2024.
In 2025, 7 companies reported engagement with Indiana’s surgeons worth $30K in consulting, speaking, meals and travel tied to these products, about $10K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 15 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.